You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

TRETINOIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tretinoin patents expire, and what generic alternatives are available?

Tretinoin is a drug marketed by Barr Labs Inc, Endo Operations, Glenmark Pharms Ltd, Alembic, Allergan, Padagis Us, Taro, Zo Skin Health, Zydus Lifesciences, Mylan, Norvium Bioscience, Teva Pharms, Wockhardt, and Encube. and is included in twenty-two NDAs.

The generic ingredient in TRETINOIN is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tretinoin

A generic version of TRETINOIN was approved as tretinoin by PADAGIS US on December 24th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRETINOIN?
  • What are the global sales for TRETINOIN?
  • What is Average Wholesale Price for TRETINOIN?
Drug patent expirations by year for TRETINOIN
Drug Prices for TRETINOIN

See drug prices for TRETINOIN

Drug Sales Revenue Trends for TRETINOIN

See drug sales revenues for TRETINOIN

Recent Clinical Trials for TRETINOIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas Southwestern Medical CenterPhase 2
Genentech, Inc.Phase 2
Indonesia UniversityN/A

See all TRETINOIN clinical trials

Pharmacology for TRETINOIN
Drug ClassRetinoid
Medical Subject Heading (MeSH) Categories for TRETINOIN
Paragraph IV (Patent) Challenges for TRETINOIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RETIN-A-MICRO Gel tretinoin 0.04% 020475 1 2010-12-20
RETIN-A-MICRO Gel tretinoin 0.1% 020475 1 2010-07-08

US Patents and Regulatory Information for TRETINOIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Barr Labs Inc TRETINOIN tretinoin CAPSULE;ORAL 077684-001 Jun 22, 2007 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Padagis Us TRETINOIN tretinoin GEL;TOPICAL 075589-001 Jun 11, 2002 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Padagis Us TRETINOIN tretinoin CREAM;TOPICAL 075264-001 Dec 24, 1998 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alembic TRETINOIN tretinoin CREAM;TOPICAL 217804-001 Apr 29, 2024 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Taro TRETINOIN tretinoin CREAM;TOPICAL 211645-001 Jan 22, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms TRETINOIN tretinoin SOLUTION;TOPICAL 074873-001 Jun 19, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.